SRP-1002

N/A

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameSRP-1002
Drug Alias NameALN-6400
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionPlasminogen inhibitors
TargetsPlasminogen
Therapy Area/Indicationsvon Willebrand DiseasesTelangiectasia, Hereditary HemorrhagicMenorrhagia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlnylam Pharmaceuticals Inc
Inactive CompaniesN/A
Active Indicationsvon Willebrand DiseasesTelangiectasia, Hereditary HemorrhagicMenorrhagia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A